The main reason for this is that Taiwan’s NHI reimbursement rule for dementia drugs stipulates that patients on cholinesterase inhibitors or memantine must be re-evaluated every year, and the drugs are no longer reimbursed following disease progression or abrupt deterioration [19]. Here, BCHE is linked to dementia.